|
|
APPENDIX 1A | APPENDIX 1B | APPENDIX 2A | APPENDIX 2B | APPENDIX 3 |
APPENDIX 4 | APPENDIX 5 | APPENDIX 6 | APPENDIX 7 | APPENDIX 8 |
APPENDIX 5
Findings Using Non-Imputed Data
The following are the principal findings (Cox analyses) using non-imputed data.
| Table Appendix 5A. Cox Proportional Hazards Model for 5-year Mortality among the 4374 Patients by Study Group using Non-Imputed Data * |
|
Analysis in Presence
of Covariates without Propensity Adjustment† |
Analysis in Presence of
Covariates with Propensity Adjustment‡ |
Risk Factor |
Hazard Ratio (95% CI) |
P Value |
Hazard Ratio (95% CI) |
P Value |
Aprotinin vs. control |
1.44 (1.15 – 1.81) |
.002 |
1.32 (1.03 – 1.69) |
.029 |
Aminocaproic acid vs. control |
1.01 (0.78 – 1.31) |
.923 |
0.89 (0.67 – 1.18) |
.428 |
Tranexamic acid vs. control |
1.09 (0.80 – 1.47) |
.600 |
1.04 (0.76 – 1.43) |
.794 |
Propensity score, deciles |
― |
― |
1.06 (1.02 – 1.10) |
.003 |
Complex vs. primary surgery§ |
1.59 (1.32 – 1.91) |
<.001 |
1.48 (1.21 – 1.81) |
<.001 |
Age per 10 years or part thereof over
60 years |
1.52 (1.37 – 1.70) |
<.001 |
1.49 (1.33 – 1.66) |
<.001 |
History of congestive heart failure with
hospitalization |
1.62 (1.29 – 2.04) |
<.001 |
1.67 (1.31 – 2.12) |
<.001 |
History of valve disease without prior or
current valve surgery |
1.35 (1.04 – 1.77) |
.026 |
1.28 (0.97 – 1.69) |
.087 |
History of diabetes mellitus |
1.44 (1.20 – 1.72) |
<.001 |
1.38 (1.14 – 1.68) |
.001 |
History of pulmonary disease |
1.26 (1.04 – 1.53) |
.017 |
1.29 (1.05 – 1.58) |
.015 |
History of peripheral vascular disease |
1.43 (1.17 – 1.74) |
<.001 |
1.39 (1.13 – 1.71) |
.002 |
Medication of warfarin or coumadin in the
past week of admission |
1.70 (1.31 – 2.21) |
<.001 |
1.57 (1.19 – 2.09) |
.002 |
Creatinine > 1.3 mg/dl on admission║ |
1.81 (1.48 – 2.20) |
<.001 |
1.83 (1.49 – 2.25) |
<.001 |
Stroke on admission |
1.29 (1.08 – 1.54) |
.006 |
1.31 (1.09 – 1.59) |
.004 |
Preoperative congestive heart failure |
1.33 (1.10 – 1.61) |
.003 |
1.35 (1.10 – 1.65) |
.003 |
Preoperative myocardial infarction |
1.83 (1.17 – 2.84) |
.008 |
1.63 (1.00 – 2.65) |
.049 |
* Cohort includes patients who died in hospital and patients who survived their index hospitalization (N=4374). CI denotes confidence
interval.
† Excluded were 137 patients with missing values for at least one of the risk factors in the model, including the covariates.
‡ Excluded were 418 patients with missing values for at least one of the risk factors in the model, including the covariates.
§ Complex surgery was defined as surgery under any of the following conditions: a history of coronary-artery bypass grafting, valve surgery,
noncoronary angioplasty or stenting, or other cardiac or vascular noncardiac surgery, combined current heart surgery, or current surgery
in emergency status or urgent status with evidence of congestive heart failure preoperatively.
║To convert the value for creatinine to micromoles per liter, multiply by 88.4.
| Table Appendix 5B. Cox Proportional Hazards Model for 5-year Mortality among the 4249 Patients Who Survived Index Hospitalization by Study Group using Non-Imputed Data* |
|
Analysis in Presence of Covariates without Propensity Adjustment† |
Analysis in Presence of Covariates with Propensity Adjustment‡ |
Risk Factor |
Hazard Ratio (95% CI) |
P Value |
Hazard Ratio (95% CI) |
P Value |
Aprotinin vs. control |
1.46 (1.12 – 1.89) |
.005 |
1.40 (1.05 – 1.87) |
.021 |
Aminocaproic acid vs. control |
1.12 (0.84 – 1.50) |
.446 |
1.11 (0.81 – 1.53) |
.504 |
Tranexamic acid vs. control |
1.14 (0.80 – 1.62) |
.460 |
1.16 (0.81 – 1.68) |
.419 |
Propensity score, deciles |
― |
― |
1.02 (0.98 – 1.07) |
.281 |
Complex vs. primary surgery§ |
1.65 (1.34 – 2.02) |
<.001 |
1.60 (1.28 – 2.00) |
<.001 |
Age per 10 years or part thereof over
60 years |
1.58 (1.40 – 1.79) |
<.001 |
1.56 (1.38 – 1.78) |
<.001 |
History of smoking |
1.37 (1.08 – 1.73) |
.009 |
1.38 (1.07 – 1.78) |
.013 |
History of congestive heart failure with
hospitalization |
1.58 (1.22 – 2.06) |
<.001 |
1.52 (1.14 – 2.03) |
.004 |
History of no angina║ |
1.49 (1.13 – 1.96) |
.005 |
1.47 (1.09 – 1.99) |
.012 |
History of valve disease without prior or
current valve surgery |
1.42 (1.05 – 1.92) |
.024 |
1.39 (1.00 – 1.92) |
.049 |
History of diabetes mellitus |
1.46 (1.18 – 1.80) |
<.001 |
1.45 (1.16 – 1.81) |
.001 |
History of pulmonary disease |
1.34 (1.08 – 1.66) |
.008 |
1.45 (1.15 – 1.82) |
.002 |
History of peripheral vascular disease |
1.49 (1.20 – 1.86) |
<.001 |
1.41 (1.11 – 1.79) |
.005 |
Creatinine > 1.3 mg/dl on admission¶ |
1.55 (1.24 – 1.95) |
<.001 |
1.55 (1.22 – 1.98) |
<.001 |
Stroke on admission |
1.44 (1.18 – 1.76) |
<.001 |
1.46 (1.18 – 1.80) |
<.001 |
Preoperative myocardial infarction |
2.30 (1.41 – 3.73) |
<.001 |
2.01 (1.18 – 3.41) |
.010 |
In-hospital composite outcome events** |
1.47 (1.19 – 1.83) |
<.001 |
1.55 (1.23 – 1.95) |
<.001 |
* Cohort includes patients who survived their index hospitalization (N=4249). CI denotes confidence interval.
† Excluded were 67 patients with missing values for at least one of the risk factors in the model, including the covariates.
‡ Excluded were 403 patients with missing values for at least one of the risk factors in the model, including the covariates.
§ Complex surgery was defined as surgery under any of the following conditions: a history of coronary-artery bypass grafting, valve surgery,
noncoronary angioplasty or stenting, or other cardiac or vascular noncardiac surgery, combined current heart surgery, or current surgery
in emergency status or urgent status with evidence of congestive heart failure preoperatively.
║ No angina indicates admission to cardiac surgery without angina, and generally for other reasons, such as: heart failure, myocardial
infarction, sudden death, or failed percutaneous intervention.
¶ To convert the value for creatinine to micromoles per liter, multiply by 88.4.
** In-hospital outcome events included: cardiovascular events (myocardial infarction, congestive heart failure), cerebrovascular events
(stroke, encephalopathy), and renal events (renal dysfunction, renal failure).
|
